Previous close | 46.35 |
Open | 46.57 |
Bid | 40.00 x 800 |
Ask | 56.00 x 900 |
Day's range | 45.88 - 46.92 |
52-week range | 41.32 - 58.00 |
Volume | |
Avg. volume | 757,056 |
Market cap | 10.438B |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | 19.79 |
EPS (TTM) | 2.32 |
Earnings date | 25 Jul 2022 - 29 Jul 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 52.53 |
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
HILDEN, Germany & GERMANTOWN, Md., May 16, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.
If you want to know who really controls Qiagen N.V. ( NYSE:QGEN ), then you'll have to look at the makeup of its share...